enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Some drugmakers to cap cost of asthma inhalers at $35 a month

   www.aol.com/news/drugmakers-cap-cost-asthma...

   According to a spokesperson for AstraZeneca, both privately insured and uninsured patients will be eligible for the $35 price cap, which will apply to all of the inhalers the drugmaker sells in ...

3. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

   www.aol.com/news/astrazeneca-cap-us-pocket-costs...

   Boehringer had also said it would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1. ... including inhalers to treat asthma and ...

4. AstraZeneca capping COPD, asthma medications at $35 a month - AOL

   www.aol.com/news/astrazeneca-capping-copd-asthma...

   For premium support please call: 800-290-4726 more ways to reach us

5. Health insurance coverage in the United States - Wikipedia

   en.wikipedia.org/wiki/Health_insurance_coverage...

   In 2019 Gallup found that 25% of U.S. adults said they or a family member had delayed treatment for a serious medical condition during the year because of cost, up from 12% in 2003 and 19% in 2015. For any condition, 33% reported delaying treatment, up from 24% in 2003 and 31% in 2015. [24] Coverage gaps also occur among the insured population.

6. Affordable Insulin Now Act - Wikipedia

   en.wikipedia.org/wiki/Affordable_Insulin_Now_Act

   The Affordable Insulin Now Act is a bill in the United States Congress intended to cap out-of-pocket insulin prices under private health insurance and Medicare at no more than $35 per month. [ 1 ] The bill was first introduced on February 25, 2022, by Representative Angie Craig ( D - MN ). [ 2 ]

7. Pharmaceutical Benefits Scheme - Wikipedia

   en.wikipedia.org/wiki/Pharmaceutical_Benefits_Scheme

   In 1944, the Curtin Labor government passed the Pharmaceutical Benefits Act 1944 [1] [2] as part of a wider plan to create a British-style National Health Service.The Act was an extension of the similar Repatriation Pharmaceutical Benefits Scheme established in 1919 for Australian servicemen and women who had served in the Boer War and World War I.